Headquartered in San Diego, CA Fiscal year ends December NASDAQ: HALO halozyme.com
Halozyme Therapeutics is a biopharmaceutical company that develops and licenses proprietary drug delivery technologies enabling subcutaneous administration of injectable drugs and biologics. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery, reducing treatment burden for patients. ENHANZE is commercially validated with ten products launched across over 100 global markets and is licensed to major pharmaceutical partners including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, GSK, and Incyte. The company generates revenue primarily through royalties on partner product sales, product sales of bulk rHuPH20 enzyme, and collaborative agreement revenues including upfront and milestone payments. Halozyme has expanded its technology portfolio through acquisitions of Elektrofi (November 2025) and Surf Bio (Q4 2025), adding Hypercon microparticle technology and polymer-based hyperconcentration technology that complement ENHANZE by enabling creation and delivery of highly concentrated biologics. Hypercon is licensed to partners including Janssen, Eli Lilly, argenx, Vertex Pharmaceuticals, and Oruka Therapeutics. The company also develops, manufactures and commercializes drug-device combination products using auto-injector technologies, with two proprietary commercial products: Hylenex and XYOSTED. Updated
Live Updates No updates were posted during this live coverage. Here are a few recent upgrades you may want to pay attention to. Palantir Technologies Palantir Technologies (NYSE: PLTR | PLTR Price…
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you’re investing…
Thursday's top analyst upgrades and downgrades included Airbnb, Alcon, Antero Midstream, Exact Sciences, GitLab, GlobalFoundries, Halozyme Therapeutics, Lumentum, Nektar Therapeutics, PayPal and Southern Copper.
Monday’s top analyst upgrades and downgrades included Chipotle Mexican Grill, CRISPR, Hess Midstream, iMedia Brands, Kinder Morgan, Wendy’s and more.
Monday's top analyst upgrades and downgrades included Foot Locker, Halozyme Therapeutics, Kimberley-Clark, Occidental Petroleum, Texas Roadhouse, Trip.com and Williams Companies.
Thursday's top analyst upgrades and downgrades included Alphabet, Chevron, Citigroup, Facebook, Fastly, Paypal, Snap, Twitter and Under Armour.
The top analyst upgrades, downgrades and initiations seen on Thursday include Aetna, Analog Devices, Lowe's, Merck, Pfizer, Plug Power, Qualcomm and Target.
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
Halozyme Therapeutics saw its shares make a handy gain early on Thursday after the firm announced that it licensed its Enhanze drug-delivery technology to Roche for exclusive development of an “undisclosed therapeutic…
Chris Lange As the markets are continuing to heat up, a few biopharma stocks made massive gains on Thursday. There is a very positive sentiment in the health care sector in anticipation of the…
Over the past week, Halozyme Therapeutics and a couple of other biotech companies made impressive runs.
These biotech companies stood out from the rest with big moves over the course of the past week.
Halozyme Therapeutics hit a new 52-week low in Monday's session following the release of a business update at JPMorgan’s 34th Annual Healthcare Conference.
Chris Lange Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.
Many investors are looking for where to put their money now that the Dow Jones Industrial Average has hit 18,000.
Halozyme Therapeutics is a biopharmaceutical company that develops and licenses proprietary drug delivery technologies enabling subcutaneous administration of injectable drugs and biologics.
24/7 Wall St.'s 12-month price target for HALO is $100.54, rated Hold. The Wall Street consensus target is $102.11. HALO price prediction →
